Patient P-01304
Synthetic patientNBL-101 · Day 116 · 25–34 · M · baseline S12Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Favorable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
6%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S12
- Day 19 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 60 GI-04 recommended — GI Support Protocol GI-04
- Day 61 Patient declined — Not now
What changed?
Trajectory began diverging from predicted response on Day 19.
Primary contributors, last 14 days
- GI instability-21
- Nutritional resilience+12
- Inflammatory activity-6
- Treatment adherence+3
What helped?
- GI Support Protocol GI-04Day 60Declined by patient
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion4.8/100
improving · -13.4 vs previous 14 d
Toxicity
Blood16.6/100
worsening · +7.5 vs previous 14 d
Sleep quality
Wearable75.7/100
improving · +5.5 vs previous 14 d
Energy level
Daily log6.4/10
stable · -0.1 vs previous 14 d
Stress level
Daily log3.4/10
improving · -0.4 vs previous 14 d
Steps
Wearable10,018
improving · +753 vs previous 14 d
Adherence
Companion89.4 %
stable · -3.4 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards restoration · 91 from the failing basin, 21 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
Would not help
- Keep histamine lowGI +5.7 next day on high-intake days · n 28
- Keep alcohol lowGI +4.8 next day on high-intake days · n 23
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Histamine load+5.7detractor · 95%
- Alcohol+4.8detractor · 95%
- Simple carbohydrates-0.8no signal · 15%
- Spicy / capsaicin-0.6no signal · 15%
- Dietary fat load-0.1no signal · 15%
- Insoluble fibre0no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Autonomic recovery ↑25
- WearableResting HR 73 bpm
- Inflammatory signalling ↓20
- MicrobiomeBacteroides fragilis expansion
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.4 · butyrate capacity 55/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 71 ms
- Sleep
- 7.4 h
- Steps
- 8,612
- Resting HR
- 75 bpm
Daily log: GI score 5, nutritional resilience 73, adherence 89.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.